PDC*line Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Intermediary results of high dose PDC lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and.
LIÈGE, Belgium & GRENOBLE, France, April 08, 2024 PDC line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC lung01.
Human Isolated Peripheral Blood Mononuclear Cells (PBMCs) from BioIVT come from normal donors and are commonly utilized in drug discovery and development.